The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.
Read More
In a Nod to Precision Oncology, the FDA Approves Revumenib
The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.
Read More